Clinical Trial

Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMS

Suspended Phase 2
View on ClinicalTrials.gov →
Why the trial stopped
PI Request
Summary
To find out if receiving standard chemotherapy (doxorubicin and trabectedin) can extend the cancer-free survival of patients with Stage 1b/2 uterine leiomyosarcoma who had surgery that fully removed the tumor.
Protocol Amendment History 1 change
critical Recruitment suspended 2026-06-30
Trial Details
NCT Number NCT07076186
Lead Sponsor M.D. Anderson Cancer Center
Conditions Uterine Leiomyosarcoma
Enrollment 48 participants
Start Date 2025-10-02
Primary Completion 2027-12-02 (estimated)
Study Completion 2029-12-02 (estimated)
Updated on ClinicalTrials.gov 2026-07-30